A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE).

Abstract

Angiosarcoma and epithelioid hemangioendothelioma (EHE) are two rare vascular sarcomas with limited therapeutic options. Prior reports have shown sensitivity to microtubule-targeting agents in these histologies. We report the efficacy and safety of eribulin in these two vascular sarcomas in a pooled analysis of two parallel phase 2 studies. Patients over age 18 years with metastatic or recurrent angiosarcoma or EHE were treated with eribulin (1.4 mg/m2 on days 1 and 8 of a 21-day cycle) until progression or unacceptable toxicity. The primary endpoint was objective response rate by RECIST 1.1. 29 patients were accrued to the study, 25 (85%) having had prior taxane exposure. We observed an objective response rate (ORR) of 17% for angiosarcomas, with 6/23 (26%) patients achieving disease stability for greater than 6 months, and for EHE an ORR of 33% (2/6) with 2/6 continuing treatment for over 12 months. Five patients experienced a >1.3-fold time to progression ratio (TTP2/TTP1) on eribulin compared to the immediately prior therapy. Eribulin tolerability was consistent with published data. Eribulin showed clinical activity in this largely taxane-pretreated population. Future studies will be needed to confirm activity.